» Articles » PMID: 30662625

Individualized Screening for Chaperone Activity in Gaucher Disease Using Multiple Patient Derived Primary Cell Lines

Overview
Journal Am J Transl Res
Specialty General Medicine
Date 2019 Jan 22
PMID 30662625
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The knowledge of individual response to a therapy, which can be assesed by screening, is essential for the development of therapeutics. Chaperone therapy is based on the ability of small molecules to fold the mutant protein to recover its function. As a novel approach for the treatment of Gaucher disease (GD), ambroxol was recently identified as a chaperone for GD, caused by the pathogenic variants in gene, resulting in lysosomal enzyme glucocerebrosidase (GCase) deficiency. Since ambroxol activity is mutation-dependent, the assessment of the chaperone action requires adaptation of a cell model with genetic format identical to the patient. We compared the chaperone activity of ambroxol using different primary cells derived from GD patients with different genotypes. Ambroxol enhanced GCase activity in cells with wild type and in those, compound heterozygous for N370S, but was ineffective in cell lines with complex GBA alleles. In cells from patients with neuropathic GD and L444P/L444P genotype, the response to ambroxol was varied. We conclude that chaperone activity depends on diverse factors in addition to a particular genotype. We showed that PBMCs and macrophages are the most relevant cell-based methods to screen the efficacy of ambroxol therapy. For pediatric patients, a non-invasive source of primary cells, urine derived kidney epithelial cells, have a vast potential for drug screening in GD. These findings demonstrate the importance of personalized screening to evaluate efficacy of chaperone therapy, especially in patients with neuronopathic GD.

Citing Articles

The Expression and Secretion Profile of TRAP5 Isoforms in Gaucher Disease.

Ivanova M, Dao J, Loynab N, Noor S, Kasaci N, Friedman A Cells. 2024; 13(8.

PMID: 38667330 PMC: 11049511. DOI: 10.3390/cells13080716.


Rapid and long-lasting efficacy of high-dose ambroxol therapy for neuronopathic Gaucher disease: A case report and literature review.

Higashi K, Sonoda Y, Kaku N, Fujii F, Yamashita F, Lee S Mol Genet Genomic Med. 2024; 12(4):e2427.

PMID: 38553911 PMC: 10980885. DOI: 10.1002/mgg3.2427.


Potential Binding Sites of Pharmacological Chaperone NCGC00241607 on Mutant β-Glucocerebrosidase and Its Efficacy on Patient-Derived Cell Cultures in Gaucher and Parkinson's Disease.

Kopytova A, Rychkov G, Cheblokov A, Grigoreva E, Nikolaev M, Yarkova E Int J Mol Sci. 2023; 24(10).

PMID: 37240451 PMC: 10219579. DOI: 10.3390/ijms24109105.


Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease.

Ivanova M, Dao J, Kasaci N, Adewale B, Nazari S, Noll L PLoS One. 2021; 16(10):e0247211.

PMID: 34695170 PMC: 8544834. DOI: 10.1371/journal.pone.0247211.


Parkinson's Disease Associated with GBA Gene Mutations: Molecular Aspects and Potential Treatment Approaches.

Senkevich K, Kopytova A, Usenko T, Emelyanov A, Pchelina S Acta Naturae. 2021; 13(2):70-78.

PMID: 34377557 PMC: 8327146. DOI: 10.32607/actanaturae.11031.


References
1.
Boven L, van Meurs M, Boot R, Mehta A, Boon L, Aerts J . Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol. 2004; 122(3):359-69. DOI: 10.1309/BG5V-A8JR-DQH1-M7HN. View

2.
Goker-Alpan O, Hruska K, Orvisky E, Kishnani P, Stubblefield B, Schiffmann R . Divergent phenotypes in Gaucher disease implicate the role of modifiers. J Med Genet. 2005; 42(6):e37. PMC: 1736082. DOI: 10.1136/jmg.2004.028019. View

3.
Butters T . Gaucher disease. Curr Opin Chem Biol. 2007; 11(4):412-8. DOI: 10.1016/j.cbpa.2007.05.035. View

4.
Zheng W, Padia J, Urban D, Jadhav A, Goker-Alpan O, Simeonov A . Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc Natl Acad Sci U S A. 2007; 104(32):13192-7. PMC: 1936979. DOI: 10.1073/pnas.0705637104. View

5.
Beeh K, Beier J, Esperester A, Paul L . Antiinflammatory properties of ambroxol. Eur J Med Res. 2008; 13(12):557-62. View